SEC Form 4 · accession 0001209191-15-060930
AMICUS THERAPEUTICS, INC. · FOLD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John F Crowley
Officer — Chairman & CEO · Director
Period of report
Jul 13, 2015
Accepted (ET)
Jul 15, 2015 · 5:02 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001178879
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Jul 13, 2015 | M | 7,750 | $15.0084 | A | 91,249 | D | |
| Common StockF3 | Jul 13, 2015 | S | 7,750 | $15.0084 | D | 83,499 | D | |
| Common StockF4 | Jul 14, 2015 | M | 142,250 | $15.0276 | A | 225,749 | D | |
| Common StockF5 | Jul 14, 2015 | S | 142,250 | $15.0276 | D | 83,499 | D | |
| Common Stock | holding | — | — | — | 64,895 | I | By Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options (right to buy) | $4.16 | Jul 13, 2015 | M | 7,750 | D | Nov 1, 2013 | Nov 16, 2019 | Common Stock | 7,750 | 142,250 | D |
| Stock Options (right to buy) | $4.16 | Jul 14, 2015 | M | 142,250 | D | Nov 1, 2013 | Nov 16, 2019 | Common Stock | 142,250 | 0 | D |
Explanation of responses
- F1The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 17, 2014.
- F2This price is the weighted average purchase price for the transactions reported on this line. The prices for the transactions reported on this line range from $15.00 to $15.06. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
- F3This price is the weighted average sale price for the transactions reported on this line. The prices for the transactions reported on this line range from $15.00 to $15.06. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F4This price is the weighted average purchase price for the transactions reported on this line. The prices for the transactions reported on this line range from $15.00 to $15.10. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
- F5This price is the weighted average sale price for the transactions reported on this line. The prices for the transactions reported on this line range from $15.00 to $15.10. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
Remarks
The stock options exercised under this Rule 10b5-1 trading plan were due to expire on November 16, 2019. After this transaction, Mr. Crowley holds stock options for approximately 2 million shares of Amicus Therapeutics, Inc. common stock.